MARKET

TRDA

TRDA

Entrada Therapeutics, Inc.
NASDAQ
6.37
-0.63
-9.00%
After Hours: 5.50 -0.87 -13.66% 16:27 06/05 EDT
OPEN
6.93
PREV CLOSE
7.00
HIGH
7.14
LOW
6.34
VOLUME
195.03K
TURNOVER
--
52 WEEK HIGH
16.45
52 WEEK LOW
4.930
MARKET CAP
247.29M
P/E (TTM)
-1.5934
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 1d ago
Oppenheimer Remains a Buy on Entrada Therapeutics Inc (TRDA)
TipRanks · 3d ago
Analysts’ Top Healthcare Picks: Zenas BioPharma, Inc. (ZBIO), Entrada Therapeutics Inc (TRDA)
TipRanks · 3d ago
Entrada Therapeutics posts corporate deck outlining Duchenne muscular dystrophy, DM1 clinical pipeline milestones
PUBT · 4d ago
Entrada Advances Duchenne Muscular Dystrophy Drug to Higher Dose Cohort, Safety Review Clears Next Stage of Clinical Trial
Benzinga · 4d ago
Entrada Therapeutics clears 10 mg/kg Cohort 2 start in ELEVATE-45-201 DMD trial for ENTR-601-45
PUBT · 4d ago
ENTRADA THERAPEUTICS - ON TRACK TO REPORT ELEVATE-45-201 COHORT 1 DATA IN MID-2026
Reuters · 4d ago
Entrada Therapeutics grants 18,600 inducement RSUs to new hires under 2025 equity plan
PUBT · 5d ago
More
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.

Webull offers Entrada Therapeutics Inc stock information, including NASDAQ: TRDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRDA stock methods without spending real money on the virtual paper trading platform.